The following is a summary of "Bronchiectasis In Patients With Inflammatory Bowel Diseases – Prevalence, Predictors, And ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

Fortis Hospital, Anandapur has launched the dedicated lung failure clinic, a first-of-its-kind super-specialty outpatient service tailored to patients battling chronic and progressive respiratory ...

Sanofi today shared new progress from its mid- to late-stage respiratory pipeline, including preliminary phase 2 results for amlitelimab in adults with moderate-to-severe asthma.

Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for ...

Sanofi's respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous inflammatory asthmaLunsekimig ...

Measles is more than a rash, runny nose and a fever—it can cause brain swelling, blindness and wipe out the immune system's ...

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains ...

Percent-predicted FEV1 measured before pregnancy did not fall 1 year after in women with highly effective cystic fibrosis ...

SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on ...